31 recruiting. 31 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 31 | Recruiting 31 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-09-22 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 4 | Recruiting | Beijing Tongren Hospital | 88 | 2025-11-25 | 2026-01-21 |
| Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-11-01 | 2025-12-08 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 279 | 2025-05-20 | 2026-03-02 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 787 | 2025-05-20 | 2026-03-02 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure Acalabrutinib, Investigator's choice of treatment - Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | Phase 4 | Recruiting | AstraZeneca | 60 | 2025-02-04 | 2026-09-24 |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma Dexamethasone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 4 | Recruiting | St. Jude Children's Research Hospital | 850 | 2024-12-26 | 2026-07-14 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Axicabtagene Ciloleucel - Lymphoma, B-Cell | Phase 4 | Recruiting | Zhengzhou University | 20 | 2024-09-30 | 2024-10-15 |
| A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India Brentuximab Vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 4 | Recruiting | Takeda | 124 | 2024-08-28 | 2026-02-23 |
| Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis Hydroxychloroquine, Placebo - Sarcoidosis, Pulmonary | Phase 4 | Recruiting | Hospices Civils de Lyon | 140 | 2024-07-30 | 2026-09-17 |
| RCT of Nintedanib in Fibrotic Sarcoidosis Nintedanib, Standard of care - Sarcoidosis, Pulmonary | Phase 4 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 120 | 2024-06-30 | 2024-10-23 |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| Belimumab After Rituximab in Resistant Primary Juvenile SS Rituximab, Belimumab - Sjogren's Syndrome, Pediatric ALL | Phase 4 | Recruiting | Peking Union Medical College Hospital | 15 | 2024-03-09 | 2024-05-16 |
Showing 20 of 31. Sign in to see all of them.
Multiple Myeloma (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (2) · Neoplasms (2) · Recurrence (2) · Sarcoidosis (2) · Sarcoidosis, Pulmonary (2) · Burkitt Lymphoma (1) · Cytokine Release Syndrome (1) · Febrile Neutropenia (1) · Hodgkin Disease (1)
Hemic and Lymphatic Diseases (31) · Immune System Diseases (31) · Immunoproliferative Disorders (28) · Neoplasms by Histologic Type (28) · Neoplasms (26) · Lymphatic Diseases (21) · Hematologic Diseases (19) · Blood Protein Disorders (10) · Cardiovascular Diseases (10) · Hemorrhagic Disorders (10) · Hemostatic Disorders (10) · Leukemia, Lymphoid (10) · Lymphoma (10) · Paraproteinemias (10)
Dexamethasone (5) · Rituximab (5) · Lenalidomide (3) · pirtobrutinib (3) · 13-valent pneumococcal vaccine (2) · 23-valent pneumococcal capsular polysaccharide vaccine (2) · Calcium Dobesilate (2) · Cytarabine (2) · Doxorubicin (2) · Methotrexate (2) · Standard of Care (2) · Vincristine (2) · obinutuzumab (2) · tocilizumab (2) · 4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2 (S-S bridged) (1)
Eli Lilly and Company (3) · The First Affiliated Hospital of Soochow University (2) · Ain Shams University (1) · AstraZeneca (1) · Beijing Tongren Hospital (1) · CHU de Quebec-Universite Laval (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Gadjah Mada University (1) · Hospices Civils de Lyon (1) · Janssen Research & Development, LLC (1) · Lixia Sheng (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Peking Union Medical College Hospital (1)
China (12) · United States (12) · France (6) · Japan (5) · Australia (4) · Canada (4) · Italy (4) · Poland (4) · Spain (4) · United Kingdom (4) · Belgium (2) · Czechia (2) · Egypt (2) · India (2) · Israel (2)
Adrian U Wiestner, M.D. (1) · Ann Silk, MD (1) · Ashraf M Alaa, BSc of clinical pharmacy (1) · Christine Chen, Dr. (1) · Connie Hsia, MD (1) · Dr Vincent Laroche, MD,FRCPC (1) · Joseph Rimando, MD (1) · Liang Wang, MD (1) · Manal El-Sayed, MD (1)
PMID 15225842, PMID 15770833, PMID 23317527, PMID 24157819, PMID 24753153, PMID 27053725, PMID 31554370
2023 (2), P30CA138292 (1)